Satellos Bioscience Inc Com V.ICO

RE:RE:going to add a couple hundred thousand today

[Hampooo]

With the initiation of the phase 1 study, the company expects higher research and development costs for the duration of this Australian phase 1 clinical trial, which will be partially offset by refundable cash tax credits the company expects to receive. Currently, Australian R&D reimbursement rates for qualified companies may be up to a maximum of 43.5 per cent. At March 31, 2018, the company has accrued an estimated R&D refundable cash tax credit of $202,327, assuming full reimbursement rates